)
Davion Healthcare (DAVI) investor relations material
Davion Healthcare Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Pre-revenue developer of non-invasive home tests; four products are market-ready, with BreastCheck first in line for commercialization.
Licensing model delegates manufacturing, regulatory compliance, marketing and distribution to partners; NeuRX is the sole licensee and commercialization partner for BreastCheck.
Financial highlights
FY2025 revenue was €0; operating loss was €824k versus €1.3m in FY2024, mainly reflecting lower executive and director compensation accruals after fees were waived.
Net loss was €824k versus €1.32m; basic and diluted EPS were €(0.03) versus €(0.06).
Cash at December 31, 2025 was €1,058; related-party advances totaled €908k, while total assets were €65.1m.
Outlook and guidance
No revenue is expected before H2 2026 at the earliest; NeuRX targets a U.S. BreastCheck launch in H2 2026, followed by international launches from 2027, subject to market conditions.
Contractual cash inflows are expected to begin in July 2026; timing and amounts depend on NeuRX’s commercialization and performance.
FY2025 costs are not representative of FY2026: listing-related fees and higher public-company costs for executives, directors, legal, insurance, accounting, technology and compliance are expected.
- A no-proceeds direct listing puts a pre-revenue home-diagnostics platform on Nasdaq.DAVI
Registration filing - A no-proceeds direct listing precedes a high-stakes, license-led commercialization ramp.DAVI
Registration filing - A no-proceeds direct listing precedes a high-stakes 2026 product launch and licensing ramp.DAVI
Registration filing - A no-proceeds direct listing precedes the first expected product launch in H1 2026.DAVI
Registration filing
Next Davion Healthcare earnings date
Next Davion Healthcare earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)